Analyst Reco. OptimizeRx Corporation

Stocks

OPRX

US68401U2042

Internet Services

Real-time Estimate Cboe BZX Other stock markets 12:35:50 2026-06-11 EDT			5-day change	1st Jan Change
5.075 ^USD	-0.10%		-6.69%	-59.05%

06-05	OptimizeRx Corporation Announces Resignation of Theresa Greco as Chief Commercial Officer Role, Effective June 15, 2026	CI
05-21	OptimizeRx Corp. Integrates Proprietary Electronic Health Record Network Into DeepIntent Healthcare Advertising Platform	CI

Analyst Reco.

05-13	B. Riley Adjusts Price Target on OptimizeRx to $10 From $11, Maintains Buy Rating	MT
03-06	B. Riley Adjusts OptimizeRx Price Target to $11 From $28, Maintains Buy Rating	MT
11-07	B. Riley Adjusts Price Target on OptimizeRx to $28 From $18, Maintains Buy Rating	MT
25-08-07	Digital health firm OptimizeRx beats Q2 revenue view, raises FY guidance	RE
25-05-13	B. Riley Adjusts Price Target on OptimizeRx to $18 From $13, Maintains Buy Rating	MT
25-01-08	RBC Downgrades OptimizeRx to Sector Perform From Outperform, Cuts Price Target to $6 From $7	MT
24-12-24	B. Riley Cuts Price Target on OptimizeRx to $13 From $17, Keeps Buy Rating	MT
24-12-20	Stephens Initiates Coverage on OptimizeRx With Equal Weight Rating, $5.50 Price Target	MT
24-11-14	B. Riley Lowers Price Target on OptimizeRx to $17 From $18.50, Keeps Buy Rating	MT
24-11-14	RBC Cuts Price Target on OptimizeRx to $7 From $14, Keeps Outperform Rating	MT
24-08-16	RBC Adjusts OptimizeRx's PT to $14 From $17, Maintains Outperform Rating	MT
24-04-04	JMP Securities Initiates Coverage on OptimizeRx With Market Perform Rating, $15 Price Target	MT
24-01-10	RBC Adjusts OptimizeRx's Price Target to $17 From $14, Keeps Outperform Rating	MT
24-01-03	Barclays Starts OptimizeRx With Equalweight Rating, $15 Price Target	MT
23-08-15	Roth MKM Adjusts Price Target on OptimizeRx to $20 From $31, Maintains Buy Rating	MT
23-08-15	Lake street Adjusts OptimizeRx Price Target to $13 From $18, Maintains Buy Rating	MT
23-08-15	Stifel Adjusts Price Target on OptimizeRx to $13 From $16, Maintains Buy Rating	MT
23-08-15	B. Riley Cuts OptimizeRx's Price Target to $18 From $28 on Muted H2 Revenue Expectation, Keeps Buy Rating	MT
23-08-15	RBC Cuts Price Target on OptimizeRx to $14 From $18, Says 'Persisting Macro Headwinds Dampen' 2023 Outlook, Keeps Outperform Rating	MT
23-03-09	B. Riley Securities Lowers OptimizeRx's Price Target to $28 From $30 After 'Slight' Q4 Miss, Keeps Buy Rating	MT
23-03-09	RBC Cuts Price Target on OptimizeRx to $18 From $22 After 'Disappointing' 2023 Guidance; Outperform Rating Kept	MT
23-02-02	B. Riley Resumes OptimizeRx at Buy With $30 PT, Notes Increased Pharma Ad Spend on Digital Channels as Key Market Tailwind	MT
22-11-01	Stifel Starts OptimizeRx at Buy With $19 Price Target	MT
22-08-10	B. Riley Securities Lowers OptimizeRx's Price Target to $37 from $56 After Lower-than-Expected Q2 Results, Keeps Buy Rating	MT
22-08-10	SVB Securities Adjusts OptimizeRx's Price Target to $30 from $38, Keeps Outperform Rating	MT